Earning Analysis
Welcome to our in-depth analysis of Agios Pharmaceuticals Inc(AGIO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Agios Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-30 | Pre-Market | -1.93 | -1.78 | +7.77 | 10.61M | 12.88M | +21.34 | +2.91 | -4.67 |
| FY2025Q2 | 2025-07-31 | Pre-Market | -1.74 | -1.93 | -10.92 | 9.52M | 12.46M | +30.87 | -0.85 | -3.54 |
| FY2025Q1 | 2025-05-01 | Pre-Market | -1.80 | -1.55 | +13.89 | 9.68M | 8.73M | -9.81 | +4.21 | -4.61 |
| FY2024Q4 | 2025-02-13 | Pre-Market | -1.73 | -1.74 | -0.58 | 9.35M | 10.73M | +14.79 | +1.49 | +2.86 |
| FY2024Q3 | 2024-10-31 | Pre-Market | 16.69 | 16.22 | -2.82 | 9.50M | 8.96M | -5.66 | -4.04 | +11.43 |
| FY2024Q2 | 2024-08-01 | - | -1.58 | -1.69 | -6.96 | 9.31M | 8.62M | -7.44 | -4.09 | -8.25 |
| FY2024Q1 | 2024-05-02 | - | -1.64 | -1.45 | +11.59 | 8.37M | 8.19M | -2.19 | +2.73 | -3.57 |
| FY2023Q4 | 2024-02-15 | - | -1.64 | -1.72 | -4.88 | 7.92M | 7.10M | -10.36 | +3.47 | +14.98 |
| FY2023Q3 | 2023-11-02 | - | -1.69 | -1.64 | +2.96 | 7.53M | 7.40M | -1.69 | -1.41 | +5.63 |
| FY2023Q2 | 2023-08-03 | - | -1.60 | -1.51 | +5.63 | 6.46M | 6.71M | +3.86 | -0.15 | +0.35 |
AGIO Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Agios Pharmaceuticals Inc reported performance for FY2025Q3, announced on 2025-10-30. The company achieved an EPS of -1.78, compared to analyst estimates of -1.93 by 7.77% . Revenue for the quarter reached 12.88M compared to expectations of 10.61M by 21.34% .
The stock price reacted with a 2.91% one-day change and a -4.67% five-day change following the earnings release. These movements reflect market reaction in Agios Pharmaceuticals Inc growth trajectory and strategic initiatives.
AGIO Earnings Forecast
Looking ahead, Agios Pharmaceuticals Inc(AGIO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 12.04M and an EPS of -1.95.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 3.37%, while EPS estimates have been Revise Downward by -5.02%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -6.47% . These revisions correlate with a -23.85% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Agios Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between AGIO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+3.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-5.02%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-6.47%
In Past 3 Month
Stock Price
Go Down
-23.85%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:46.10M
--
EPS Estimate-Annual FY 2025:-7.04
—
Stock Price27.42
AGIO Revenue and EPS Performance: A Historical Perspective
Agios Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-30,Pre-Market):
EPS: -1.78 (Actual) vs.-1.93 (Estimate) (7.77%)
Revenue: 12.88M (Actual) vs. 10.61M (Estimate) (21.34%)
Price Reaction: 2.91%(1-Day), -4.67%(5-Day)
FY2025Q2 (2025-07-31,Pre-Market):
EPS: -1.93 (Actual) vs.-1.74 (Estimate) (-10.92%)
Revenue: 12.46M (Actual) vs. 9.52M (Estimate) (30.87%)
Price Reaction: -0.85%(1-Day), -3.54%(5-Day)
FY2025Q1 (2025-05-01,Pre-Market):
EPS: -1.55 (Actual) vs.-1.80 (Estimate) (13.89%)
Revenue: 8.73M (Actual) vs. 9.68M (Estimate) (-9.81%)
Price Reaction: 4.21%(1-Day), -4.61%(5-Day)
Earnings Reaction
The chart below shows how AGIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AGIO sees a -2.13% change in stock price 10 days leading up to the earnings, and a +4.84% change 10 days following the report. On the earnings day itself, the stock moves by +0.43%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 0.14% on the day following the earnings release and then changed by -1.48% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings Call Summary
Neutral
2025-10-30
The earnings call presents mixed signals. Financial performance shows a solid revenue increase, but rising R&D and SG&A expenses could strain resources. The pending FDA approval and REMS program pose risks to PYRUKYND's market entry. However, the company has a robust cash position and is advancing its pipeline. Q&A reveals concerns about regulatory hurdles and commercial execution challenges. Given the company's small market cap, these factors balance out to a neutral sentiment, suggesting a stock price movement between -2% and 2% over the next two weeks.
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Summary
Positive
2025-07-31
The earnings call reveals strong financial performance with a 45% YoY revenue increase and solid cash reserves, which are positive indicators. The Q&A section highlighted concerns about FDA engagement and safety profiles but didn't reveal significant risks. Upcoming product launches, especially PYRUKYND for thalassemia, are expected to drive future revenue. The market cap suggests moderate sensitivity to news, but the overall positive outlook and strategic product developments point to a likely positive stock price movement in the short term.
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Summary
Neutral
2025-05-01
The earnings call presents a mixed outlook. Financial performance shows modest growth, but guidance remains flat. Product development is promising, with upcoming launches and regulatory filings, yet regulatory risks and competition pose challenges. Market strategy is cautiously optimistic with a focus on thalassemia. Expenses have risen, but financial health remains strong with substantial cash reserves. Shareholder returns are stable, but not exceptional. The Q&A highlights uncertainties in regulatory processes and pricing. Overall, the market cap suggests moderate sensitivity to these factors, leading to a neutral stock price prediction.
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Summary
Positive
2025-02-19
The earnings call reveals a strong financial position with a notable increase in net revenue and significant milestone payments. The company is preparing for major product launches in thalassemia and sickle cell disease, indicating future growth potential. Despite increased R&D and SG&A expenses, the strategic focus on high unmet needs and market expansion, especially in the Gulf region, is promising. The Q&A highlights multibillion-dollar potential in key markets, though there are some uncertainties in clinical trials. Overall, these factors suggest a positive short-term stock price movement.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Summary
Positive
2024-10-31
The earnings call highlights strong financial metrics, including a significant cash position bolstered by milestone payments, and a 22% increase in PYRUKYND revenue. Despite risks in clinical trials, management's disciplined capital allocation and strategic focus on pipeline advancement and market expansion are promising. The Q&A indicates positive sentiment towards the company's progress in trials and market access strategies. While some concerns exist, the overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks, considering the company's market cap.
Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Summary
Neutral
2024-08-01
The earnings call presents a mixed sentiment. Financial performance shows growth in PYRUKYND revenue, but increased R&D and SG&A expenses raise concerns. The strong cash position and potential payments from the Royalty Agreement are positive. However, clinical trial risks and unclear management responses in the Q&A section contribute to uncertainty. The market cap suggests moderate reaction, leading to a neutral prediction for stock price movement.
People Also Watch
FAQ
What were the key highlights of AGIO’s latest earnings report for FY2025Q3?
How did AGIO’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for AGIO for 2025/Q4?
How does AGIO’s stock price correlate with earnings forecast revisions?
What should investors expect from AGIO’s next earnings report?